ITF Therapeutics
The Director, Brand Insights & Competitive Intelligence leads the development of market insights and competitive intelligence to support a Phase III asset launch in the neurometabolic therapeutic area. This role generates actionable insights to inform brand strategy, commercial decision-making, and launch readiness. The position involves leading market research initiatives, managing external partners, and communicating strategic findings to senior leadership and cross-functional teams.
Headquarters
Concord, Massachusetts, United States
Company Size
1-10 employees
Founded
2024
ITF Therapeutics LLC is the United States affiliate of Italfarmaco S.p.A., founded in 2024 and based in Concord, MA. The company focuses on bringing therapeutic options to people living with rare diseases, most notably commercializing DUVYZAT (givinostat), an FDA‑approved HDAC inhibitor for Duchenne muscular dystrophy (DMD), in the U.S. market. ITF combines a flexible, entrepreneurial approach with the resources and legacy of its parent organization to deliver treatments, support programs, and educational resources for patients, clinicians, and researchers.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ITF Therapeutics.
Associate Director, US Market Insights Solid Tumor/Oncology
Genmab
Director, Business Intelligence
MoonLake Immunotherapeutics
Senior Director, Market Research, Strategy & Competitive Intelligence
Azurity Pharmaceuticals
ViiV (GSK) US Competitive Intelligence & Market Research Lead
GSK plc
Associate Director, Market Research and Competitive Intelligence
BioLife Plasma Services
Sr Manager Competitive Intelligence & Market Insights
Alcon